Upcoming trial readouts
All · Readouts · AdComm · Recent approvals
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-11-05 in 1d
ESTIMATED |
READOUT
Pediatric Long-Term Follow-up and Rollover Study
Phase 4 · Diffuse Astrocytoma, Anaplastic Astrocytoma |
NVS NOVARTIS AG | dabrafenib, trametinib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-05 in 1d
ESTIMATED |
READOUT
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malig
Phase 2 · B-Cell Malignancies |
INCY INCYTE CORP | Parsaclisib, parsaclisib + itacitinib, p |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-05 in 1d
ESTIMATED |
READOUT
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metast
Phase 1/2 · Prostate Cancer |
AZN ASTRAZENECA PLC | AZD9750, AZD5305 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-09 in 5d
ESTIMATED |
READOUT
A Platform Study of Novel Immunotherapy Combinations in Participants With Previo
Phase 2 · Lung Cancer, Non-Small Cell |
GlaxoSmithKline | Pembrolizumab, Dostarlimab, Belrestotug, |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-11 in 7d
ESTIMATED |
READOUT
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metast
Phase 2 · Cervical Cancer, HPV-Related Carcinoma |
PGEN PRECIGEN, INC. | PRGN-2009 plus Pembrolizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-12 in 8d
ESTIMATED |
READOUT
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In Peop
Phase 2 · Atopic Dermatitis |
PFE PFIZER INC | PF-07275315, PF-07264660 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-13 in 9d
ESTIMATED |
READOUT
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination Wi
Phase 1/2 · Advanced Solid Tumors |
REGN REGENERON PHARMACEUTICALS, I | REGN7075, Cemiplimab, Platinum-based dou |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-13 in 9d
ESTIMATED |
READOUT
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compar
Phase 3 · Breast Cancer |
Hoffmann-La Roche | Inavolisib, Fulvestrant, Alpelisib, Bupr |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-13 in 9d
ESTIMATED |
READOUT
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity i
Phase 2 · Overweight or Obesity |
REGN REGENERON PHARMACEUTICALS, I | Olatorepatide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-14 in 10d
ESTIMATED |
READOUT
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Di
Phase 3 · Type 2 Diabetes Mellitus (T2DM) |
BrightGene Bio-Medical Technology | Drug: 5 mg BGM0504 Administered SC, Drug |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-14 in 10d
ESTIMATED |
READOUT
A Study of BGM0504 in Participants With Type 2 Diabetes
Phase 3 · Type 2 Diabetes Mellitus (T2DM) |
BrightGene Bio-Medical Technology | Drug: 5 mg BGM0504 Administered SC, Drug |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-15 in 11d
ESTIMATED |
READOUT
Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
Phase 4 · Sciatica Acute, Lumbar Spinal Stenosis |
Primus Pharmaceuticals | Metaxalone 640 mg Oral Tablet |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-15 in 11d
ESTIMATED |
READOUT
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Gla
Phase 2 · Glaucoma, Open-Angle, Ocular Hypertension |
PolyActiva Pty Ltd | PA5108 Ocular Implant low dose, PA5108 O |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-16 in 12d
ESTIMATED |
READOUT
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Gener
Phase 2/3 · Generalized Myasthenia Gravis |
UCB Biopharma SRL | Zilucoplan |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-17 in 13d
ESTIMATED |
READOUT
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Phase 2 · Gastric Cancer, Gastroesophageal Junction Cancer |
AZN ASTRAZENECA PLC | AZD0901, 5-Fluorouracil, Leucovorin, l-l |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-17 in 13d
ESTIMATED |
READOUT
A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemo
Phase 4 · Haemophilia A (Moderate or Severe), Hemophilia, Classic |
Swedish Orphan Biovitrum | Efanesoctocog alfa |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-18 in 14d
ESTIMATED |
READOUT
Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polym
Phase 2/3 · Small Cell Lung Cancer |
Han Xu, M.D., Ph.D., FAPCR, Medica | ETOPOSIDE - Usual, ETOPOSIDE - Study |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-18 in 14d
ESTIMATED |
READOUT
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucl
Phase 2/3 · Prostate Cancer |
Han Xu, M.D., Ph.D., FAPCR, Sponso | Abiraterone - Usual, Abiraterone - Study |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-18 in 14d
ESTIMATED |
READOUT
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Ac
Phase 3 · Sjögren's Syndrome |
BMY BRISTOL MYERS SQUIBB CO | Deucravacitinib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-18 in 14d
ESTIMATED |
READOUT
Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymo
Phase 2/3 · ALK-Positive Non-Small Cell Lung Cancer (NSCLC) |
Medicine Invention Design, Inc | ALECENSA - alectinib hydrochloride capsu |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-18 in 14d
ESTIMATED |
READOUT
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular D
Phase 2 · Duchenne Muscular Dystrophy |
Hoffmann-La Roche | Satralizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-18 in 14d
ESTIMATED |
READOUT
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
Phase 2 · Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) |
ToLymph Inc. | SMS001 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-19 in 15d
ESTIMATED |
READOUT
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Par
Phase 4 · Severe Hemophilia A, Moderate Hemophilia A |
Hoffmann-La Roche | Emicizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-19 in 15d
ESTIMATED |
READOUT
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participant
Phase 2 · Alzheimer's Disease |
Hoffmann-La Roche | RO7269162 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-19 in 15d
ESTIMATED |
READOUT
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatiti
Phase 2 · Dermatitis, Atopic |
Janssen Research & Development, LL | JNJ-95597528 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-20 in 16d
ESTIMATED |
READOUT
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With
Phase 3 · Endometrial Neoplasms |
Merck Sharp & Dohme LLC | Pembrolizumab, Carboplatin, Paclitaxel, |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-20 in 16d
ESTIMATED |
READOUT
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participant
Phase 2 · Moderate to Severe Asthma |
INCY INCYTE CORP | povorcitinib, ICS-LABA |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-20 in 16d
ESTIMATED |
READOUT
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-admi
Phase 2 · Obesity |
SKYE Skye Bioscience, Inc. | Nimacimab injection, Nimacimab placebo i |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-23 in 19d
ESTIMATED |
READOUT
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) V
Phase 2 · Neoplasms, Colon |
GlaxoSmithKline | Dostarlimab, CAPEOX |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-23 in 19d
ESTIMATED |
READOUT
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to He
Phase 3 · Chickenpox |
GlaxoSmithKline | Investigational varicella vaccine, Marke |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-24 in 20d
ESTIMATED |
READOUT
Avelumab Program Rollover Study
Phase 3 · Solid Tumors |
EMD Serono Research & Development | Avelumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-24 in 20d
ESTIMATED |
READOUT
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Phase 1/2 · Metastatic Prostate Cancer |
AZN ASTRAZENECA PLC | AZD0754, AZD2287 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-24 in 20d
ESTIMATED |
READOUT
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer
Phase 3 · Alzheimer Disease |
Karuna Therapeutics, Inc., a Brist | KarXT |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-24 in 20d
ESTIMATED |
READOUT
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart F
Phase 2 · Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction |
TECX Tectonic Therapeutic, Inc. | TX000045- Dose A, TX000045- Dose B |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-26 in 22d
ESTIMATED |
READOUT
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus
Phase 3 · Neoplasms |
Tesaro, Inc. | Dostarlimab, Carboplatin, Paclitaxel, Ni |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-26 in 22d
ESTIMATED |
READOUT
Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and
Phase 4 · COVID-19 |
SNY Sanofi | Omicron Subvariant-Based SARS-CoV-2 Reco |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-28 in 24d
ESTIMATED |
READOUT
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's
Phase 2 · Parkinson's Disease (PD) |
TrueBinding, Inc. | TB006 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-28 in 24d
ESTIMATED |
READOUT
A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric P
Phase 3 · Yellow Fever Immunization |
SNY Sanofi | Yellow fever vaccine (live), Yellow feve |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-29 in 25d
ESTIMATED |
READOUT
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used f
Phase 3 · Menstrual Migraine |
PFE PFIZER INC | Rimegepant, Rimegepant |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutat
Phase 1/2 · Glioblastoma Multiforme |
NTHI NEONC TECHNOLOGIES HOLDINGS, | Perillyl alcohol |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-L
Phase 3 · Cancer |
Hoffmann-La Roche | Atezolizumab, Bevacizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
Phase 1/2 · Duchenne Muscular Dystrophy |
SLDB Solid Biosciences Inc. | SGT-001 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety
Phase 1/2 · Multiple Myeloma |
Celgene | CC-92480, Bortezomib, Dexamethasone, Dar |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable
Phase 2 · Non-small Cell Lung Cancer |
Genentech, Inc. | Alectinib, Entrectinib, Vemurafenib, Cob |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MT
Phase 1/2 · Advanced MTAP-null Solid Tumors |
AMGN AMGEN INC | Anvumetostat, Docetaxel, Comparator Anvu |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage D
Phase 1/2 · Glycogen Storage Disease |
ModernaTX, Inc. | mRNA-3745 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
Pediatric Patients Aged 4 to 11 Years With APDS
Phase 3 · APDS |
Pharming Technologies B.V. | Leniolisib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte A
Phase 3 · Leukocyte Adhesion Deficiency |
AUG Therapeutics | AVTX-803 (L-Fucose) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
Phase 1/2 · Metastatic Castration-resistant Prostate Cancer |
OncoC4, Inc. | ONC-392 low, ONC-392 high, lutetium Lu 1 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal
Phase 1/2 · Mesial Temporal Lobe Epilepsy |
UniQure Biopharma B.V. | AAV9-hSyn1-miGRIK2 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Phase 2 · Eye Cancer, Primary Cancer |
AURA Aura Biosciences, Inc. | AU-011, SCS Microinjector, Laser |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
Phase 2 · Idiopathic Hypersomnia |
TAK TAKEDA PHARMACEUTICAL CO LTD | TAK-360 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
Phase 2 · Narcolepsy Type 2 |
TAK TAKEDA PHARMACEUTICAL CO LTD | TAK-360 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metast
Phase 3 · Breast Cancer |
InventisBio Co., Ltd | D-0502, Fulvestrant |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12
Phase 1/2 · KRAS G12D Mutation, Advanced Solid Cancer |
ARVN ARVINAS, INC. | ARV-806 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production C
Phase 2 · Monkeypox (Mpox) |
Bavarian Nordic | Jynneos, MVA-BN (Quail) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Pha
Phase 3 · Immune Thrombocytopenia |
SNY Sanofi | rilzabrutinib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis K
Phase 3 · Osteoarthritis Knee Pain |
Saol Therapeutics Inc | SL1002, Normal Saline |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
Investigating Ovulation Inhibition for Use as a Contraceptive
Phase 2 · Contraception |
Mylan Pharmaceuticals Inc | MR-130A-01 contraceptive transdermal pat |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE
Phase 2 · Obesity and Cardiovascular Risk |
BIOA BioAge Labs, Inc. | Oral BGE-102, Oral Placebo Matching BGE- |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-11-30 in 26d
ESTIMATED |
READOUT
Study to Assess Safety and Tolerability of KarXT With Administration of Antiemet
Phase 4 · Healthy Volunteers |
Karuna Therapeutics, Inc., a Brist | KarXT, Trimethobenzamide, Ondansetron, M |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Ly
Phase 2 · Diffuse Large B-cell Lymphoma |
KPTI Karyopharm Therapeutics Inc. | Selinexor, Selinexor, Selinexor |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Phase 1/2 · Colorectal Cancer, Pancreatic Cancer |
Lumicell, Inc. | LUM015, LUM 2.6 Imaging Device |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Phase 1/2 · Cancer, Neoplasms |
Cancer Vaccines Limited | ACIT-1 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patie
Phase 2 · Cushing Syndrome |
CORT CORCEPT THERAPEUTICS INC | relacorilant |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects Wi
Phase 3 · PAH, Pulmonary Hypertension |
UTHR UNITED THERAPEUTICS Corp | Ralinepag |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-01 in 27d
ESTIMATED |
READOUT
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Adva
Phase 3 · Prostatic Neoplasms |
Janssen Research & Development, LL | Apalutamide, Androgen Deprivation Therap |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stab
Phase 3 · Chronic Stable Angina Pectoris |
Tasly Pharmaceuticals, Inc. | T89 capsule |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Mus
Phase 2 · Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG |
TLTFF THERALASE TECHNOLOGIES INC / | Ruvidar® (TLD-1433) bladder infusion and |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
Phase 2 · Lumbar Disc Disease |
BRTX BioRestorative Therapies, In | BRTX-100, Saline |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Phase 1/2 · Metastatic Breast Cancer |
Phoenix Molecular Designs | PMD-026, fulvestrant |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Exten
Phase 4 · Ulcerative Colitis |
BHC Bausch Health Companies Inc. | Low Dose Budesonide, High Dose Budesonid |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without
Phase 2/3 · Relapsed/Refractory Diffuse Large B-cell Lymphoma |
KPTI Karyopharm Therapeutics Inc. | Selinexor (combination therapy), Selinex |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-01 in 27d
ESTIMATED |
READOUT
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumor
Phase 2 · Solid Tumor |
Intra-IMMUSG Pte Ltd | PRL3-zumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Phase 1/2 · Glioblastoma, Melanoma Stage IV |
Sapience Therapeutics | ST101, Temozolomide, Radiation |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-01 in 27d
ESTIMATED |
READOUT
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation
Phase 1/2 · Dry Age-related Macular Degeneration |
Luxa Biotechnology, LLC | RPESC-RPE-4W |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-01 in 27d
ESTIMATED |
READOUT
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
Phase 2 · Solid Tumor, Adult, Cancer |
EpicentRx, Inc. | AdAPT-001, Checkpoint Inhibitor, Immune |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administere
Phase 2/3 · AMD, nAMD |
ABBV AbbVie Inc. | ABBV-RGX-314, ABBV-RGX-314, Ranibizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Phase 2 · HER2 Positive Metastatic Breast Cancer |
Ambrx, Inc. | ARX788 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-01 in 27d
ESTIMATED |
READOUT
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergo
Phase 3 · Congenital Antithrombin Deficiency |
Octapharma | Atenativ |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Ped
Phase 3 · Primary Immunodeficiency Disease |
Kedrion S.p.A. | Kedrion IVIG 10% |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castrat
Phase 2 · Metastatic Castration-Resistant Prostate Cancer |
Zenith Epigenetics | ZEN003694, Enzalutamide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Phase 2/3 · Acute Stroke, Ischemic Stroke |
DMAC DiaMedica Therapeutics Inc. | Recombinant human tissue kallikrein |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-01 in 27d
ESTIMATED |
READOUT
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Se
Phase 2 · High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
K-Group, Beta, Inc., a wholly owne | azenosertib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Cap
Phase 2 · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF) |
Sunshine Lake Pharma Co., Ltd. | HEC585 dose A, HEC585 dose B |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractor
Phase 1/2 · Refractory Metastatic Colorectal Cancer, Solid Tumor |
Rottapharm Biotech | CR6086, AGEN2034 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyna
Phase 1/2 · Frontotemporal Dementia |
DNLI Denali Therapeutics Inc. | DNL593 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Phy
Phase 3 · Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer |
GNLX GENELUX Corp | olvimulogene nanivacirepvec, Platinum ch |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Safety and Efficacy of APG-157 in Head and Neck Cancer
Phase 2 · Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity |
Aveta Biomics, Inc. | APG-157 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due t
Phase 1/2 · Breast Neoplasms, Brain Neoplasms |
Stemline Therapeutics, Inc. | Elacestrant, Abemaciclib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Proph
Phase 3 · Hereditary Angioedema |
IONS IONIS PHARMACEUTICALS INC | Donidalorsen |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (i
Phase 2 · Multiple Myeloma |
Kite, A Gilead Company | anitocabtagene-autoleucel |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Phase 3 · Agitation, Alzheimer's Type Dementia |
Suven Life Sciences Limited | Masupirdine 50 mg, Masupirdine 100 mg |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K A
Phase 1/2 · HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer |
SynDevRx, Inc. | Evexomostat |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced
Phase 2 · Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung |
LTRN Lantern Pharma Inc. | LP-300, Pemetrexed, Carboplatin |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refra
Phase 1/2 · Lymphoma, B-Cell, Lymphoma, T-Cell |
Step Pharma, SAS | STP938 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP
Phase 1/2 · Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC) |
AP Biosciences Inc. | AP203, AP203 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotox
Phase 1/2 · LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma |
Dren Bio | DR-01 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated
Phase 3 · GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor |
RayzeBio, Inc. | RYZ101, Everolimus, Sunitinib, Octreotid |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Pat
Phase 3 · NASH, Cirrhosis, Liver |
MDGL MADRIGAL PHARMACEUTICALS, IN | Resmetirom |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study of AMDX-2011P in Participants With CAA
Phase 2 · Cerebral Amyloid Angiopathy |
Amydis Inc. | AMDX-2011P |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fus
Phase 2 · Advanced Cholangiocarcinoma, FGFR2 Fusions |
Taiho Oncology, Inc. | TAS-120 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in P
Phase 1/2 · Solid Tumor, Adult, Solid Tumor |
A2 Biotherapeutics Inc. | A2B530, xT-Onco with HLA-LOH Assay |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Phase 2 · Type 1 Diabetes Mellitus With Hypoglycemia |
Zucara Therapeutics Inc. | ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Ob
Phase 3 · Fecal Incontinence |
Cook MyoSite | Iltamiocel |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary
Phase 2 · Hypoxic-Ischemic Encephalopathy |
ReAlta Life Sciences, Inc. | RLS-0071 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Ad
Phase 1/2 · Solid Tumor, Biliary Tract Cancer |
TiumBio Co., Ltd. | TU2218 + KEYTRUDA® (Pembrolizumab) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Registrational Study of TTX-381 to Treat Vision Loss in CLN2 Disease
Phase 1/2 · Neuronal Ceroid Lipofuscinosis Type 2 |
Tern Therapeutics, LLC | TTX-381, TTX-381 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic
Phase 2 · Lymphatic Malformation |
TARA Protara Therapeutics, Inc. | TARA-002 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-
Phase 1/2 · Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma |
BEAM Beam Therapeutics Inc. | BEAM-201 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Study of ALTO-300 in MDD
Phase 2 · Major Depressive Disorder |
ANRO Alto Neuroscience, Inc. | ALTO-300 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchym
Phase 1/2 · Heart Failure, Systolic |
BCDA BioCardia, Inc. | CardiALLO™ Human Allogenic Culture-expan |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-a
Phase 3 · Cholangiocarcinoma |
TransThera Sciences (Nanjing), Inc | Tinengotinib 8 mg, Tinengotinib 10 mg, P |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced o
Phase 2 · Endometrial Cancer, Endometrioid Tumor |
Aadi Bioscience, Inc. | nab-sirolimus |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-01 in 27d
ESTIMATED |
READOUT
Descartes-08 for Patients With Systemic Lupus Erythematosus
Phase 2 · Systemic Lupus Erythematosus (SLE) |
RNAC Cartesian Therapeutics, Inc. | Descartes-08 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophi
Phase 2 · Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome |
NS Pharma, Inc. | NS-229 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study of BN104 in the Treatment of Acute Leukemia
Phase 1/2 · ALL, Adult, AML, Adult |
Institut de Recherches Internation | BN104 monotherapy, BN104 monotherapy, BN |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squ
Phase 2 · Vulvar Diseases, HPV Infection |
Frantz Viral Therapeutics, LLC | Artesunate ointment |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Part
Phase 2 · Acute Pancreatitis |
Panafina, Inc. | RABI-767 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
Phase 1/2 · Light Chain (AL) Amyloidosis |
Nexcella Inc. | NXC-201 CAR-T |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Study to Assess Adverse Events and Change in Disease Activity in Previously Trea
Phase 2 · Unresectable Metastatic Colorectal Cancer |
ABBV AbbVie Inc. | ABBV-400, Bevacizumab, Folinic Acid, Flu |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
Phase 1/2 · Arrhythmogenic Cardiomyopathy, PKP2-ACM |
LXEO Lexeo Therapeutics, Inc. | LX2020 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory
Phase 2/3 · Focal Epilepsy |
BHVN Biohaven Ltd. | BHV-7000, BHV-7000, BHV-7000 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamic
Phase 1/2 · Solid Tumor |
Alyssum Therapeutics | AT-1965 Liposome Injection |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patie
Phase 2 · NSCLC |
EIKN Eikon Therapeutics, Inc. | EIK1001, Pembrolizumab, Paclitaxel, Peme |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate C
Phase 1/2 · MRI Scan |
Songqi Gao | MT218 injection |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
ZILRETTA in Subjects With Shoulder Osteoarthritis
Phase 3 · Glenohumeral Osteoarthritis |
PCRX Pacira BioSciences, Inc. | ZILRETTA |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EX
Phase 3 · Pulmonary Arterial Hypertension |
Gossamer Bio USA, Inc. | Seralutinib, Gereic Dry Powder Inhaler |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumo
Phase 1/2 · Advanced Solid Tumor |
Latticon Antibody Therapeutics, In | LAT010, LAT010 + ICI |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-01 in 27d
ESTIMATED |
READOUT
A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC)
Phase 2 · Pressure Ulcer, Stage IV, Osteomyelitis |
Biocomposites Ltd | STIMULAN VG |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal He
Phase 2 · Paroxysmal Nocturnal Hemoglobinuria |
OMER OMEROS CORP | OMS906 study drug |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Phase 2 Study of WGI-0301 for Advanced HCC
Phase 2 · Advanced Hepatocellular Carcinoma (HCC) |
Zhejiang Haichang Biotech Co., Ltd | WGI-0301 at MTD/RP2D dose IV infusion, Q |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
SPI-1005 in Adults Receiving Cochlear Implant
Phase 2 · Hearing Loss, Cochlear Trauma |
Sound Pharmaceuticals, Incorporate | Ebselen |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalize
Phase 2 · Steroid Refractory GVHD |
ReAlta Life Sciences, Inc. | RLS-0071 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients W
Phase 3 · Acute Hereditary Angio Edema |
Octapharma | OCTA-C1-INH |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Phase 1/2 · Advanced or Metastatic Solid Tumors, Breast Cancer |
858 Therapeutics, Inc. | ETX-19477 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With o
Phase 2 · Acute Ischemic Stroke |
NoNO Inc. | NoNO-42 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using
Phase 3 · Binge-Eating Disorder |
AXSM Axsome Therapeutics, Inc. | Solriamfetol 150 mg, Solriamfetol 300 mg |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia
Phase 2 · Myasthenia Gravis, Myasthenia Gravis, MuSK |
NMD Pharma A/S | NMD670 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)
Phase 2 · Basal Cell Carcinoma |
Highlight Therapeutics | BO-112 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Phase 1/2 · Melanoma Stage IV, Solid Tumor |
Georgiamune Inc | GIM-531, Anti-PD-1 monoclonal antibody |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Long-term Safety and Tolerability of BHV-7000
Phase 2 · Focal Epilepsy |
BHVN Biohaven Ltd. | BHV-7000, BHV-7000 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active
Phase 2 · Moderately to Severely Active Crohn Disease |
ABVX Abivax S.A. | Obefazimod |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adoles
Phase 3 · Hidradenitis Suppurativa |
ABBV AbbVie Inc. | Lutikizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
Phase 2 · Multifocal Motor Neuropathy |
DNTH Dianthus Therapeutics, Inc. | Claseprubart |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shif
Phase 3 · Excessive Sleepiness, Shift-work Disorder |
AXSM Axsome Therapeutics, Inc. | Solriamfetol 150 mg, Solriamfetol 300 mg |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of Eschar
Phase 3 · Venous Leg Ulcer (VLU) |
MDWD MediWound Ltd. | EscharEx (EX-03) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone Mas
Phase 2 · Postmenopausal Osteoporosis |
Angitia Biopharmaceuticals | AGA2118 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or
Phase 1/2 · Solid Tumor |
Lamassu Bio Inc | SA53-OS (phase 1), SA53-OS (phase 2) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control
Phase 2 · Myopia, Progressive |
Sunhawk Vision Biotech, Inc. | SHJ002, Atropine |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of
Phase 3 · Eosinophilic Esophagitis |
Dr. Falk Pharma GmbH | Budesonide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given D
Phase 2 · Refractory Metastatic Colorectal Cancer |
DCTH DELCATH SYSTEMS, INC. | Melphalan/HDS Followed by Consolidation |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten R
Phase 1/2 · KRAS G12D Mutation |
Ranok Therapeutics (Hangzhou) Co., | RNK08954-01 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-01 in 27d
ESTIMATED |
READOUT
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in A
Phase 3 · Antibody-mediated Rejection |
BIIB BIOGEN INC. | Felzartamab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Tissue Repair Gel in Venous Leg Ulcers in AU/US
Phase 3 · Venous Leg Ulcer, Venous Ulcer |
TR Therapeutics | TR987 0.1% gel + Standard of Care |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus
Phase 2/3 · Microvillus Inclusion Disease, Congenital Disorders |
Napo Pharmaceuticals, Inc. | Crofelemer Powder for Oral Solution |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Phase 2 · Narcolepsy Type 1, Narcolepsy Type 2 |
Centessa Pharmaceuticals (UK) Limi | ORX750 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Wit
Phase 1/2 · Type 1 Diabetes Mellitus, T1D |
COUR Pharmaceutical Development Co | CNP-103 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-01 in 27d
ESTIMATED |
READOUT
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent
Phase 3 · Pneumococcal Infections |
SNY Sanofi | PCV21, 20vPCV |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-01 in 27d
ESTIMATED |
READOUT
Spermatogonial Differentiation Via Testicular Organoid
Phase 1/2 · Infertility, Male, Gene Abnormality |
CellARTs Inc. | Stem cell, Genetic Screening, Genetic Re |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study of Navenibart in Participants With Hereditary Angioedema
Phase 3 · Hereditary Angioedema (HAE) |
Astria Therapeutics, Inc. | navenibart |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced
Phase 2 · Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy |
DWTX Dogwood Therapeutics, Inc. | Halneuron, Halneuron (Open Label Extensi |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the
Phase 1/2 · oGHVD |
Regenerative Ocular Immunobiologic | d-MAPPS, PI and Patient Masked |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
Phase 3 · Meniere's Disease, Ménière's Disease |
Sound Pharmaceuticals, Incorporate | Ebselen |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-01 in 27d
ESTIMATED |
READOUT
Study to Evaluate the Safety and the Immunogenicity of a Second Generation Struc
Phase 1/2 · Pandemic Influenza Immunization, Healthy Volunteers |
SNY Sanofi | Pandemic flu H5 HA mRNA SD2 vaccine |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retini
Phase 2 · Retinitis Pigmentosa |
jCyte, Inc | human retinal progenitor cells, Mock inj |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Safety and Efficacy of VDPHL01 in Males With AGA
Phase 3 · Androgenetic Alopecia, AGA |
MANE Veradermics, Inc | VDPHL01 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic
Phase 1/2 · Neurotrophic Keratitis |
KRYS Krystal Biotech, Inc. | KB801 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerabil
Phase 3 · Developmental and Epileptic Encephalopathy 1 |
PRAX Praxis Precision Medicines, | 1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermo
Phase 3 · Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa |
KRYS Krystal Biotech, Inc. | KB803 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Saf
Phase 3 · Epileptic Encephalopathy, SCN2A Encephalopathy |
PRAX Praxis Precision Medicines, | 1mg elsunersen, 0.5mg elsunersen |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Sy
Phase 2 · Non-obstructive Hypertrophic Cardiomyopathy |
Imbria Pharmaceuticals, Inc. | Ninerafaxstat 200mg MR |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With
Phase 3 · Chronic Primary Immune Thrombocytopenia (ITP) |
Kedrion S.p.A. | Kedrion IVIG 10% |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemoli
Phase 2 · Chronic Pruritus of Unknown Origin |
Galderma R&D | nemolizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infect
Phase 3 · Viral Hepatitis |
VIR Vir Biotechnology, Inc. | Tobevibart, Elebsiran, Bulevirtide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (
Phase 1/2 · Parkinson's Disease (PD) |
EicOsis Human Health Inc. | EC5026 oral tablet |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by
Phase 2 · Nausea, Vomiting |
LLY ELI LILLY & Co | LY3537021, Background Chemotherapy |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifung
Phase 2 · Invasive Mould Infection |
Elion Therapeutics, Inc. | EL219, Active Comparator- IV Antifungal |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment
Phase 3 · Social Anxiety Disorder (SAD) |
VNDA Vanda Pharmaceuticals Inc. | VQW-765 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With
Phase 2 · Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus |
Ventus Therapeutics U.S., Inc. | VENT-03 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Phase 2 · Atopic Dermatitis (AD) |
Enveda Therapeutics | ENV-294 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
Phase 2 · Asthma |
Enveda Therapeutics | ENV-294 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
Phase 2 · Pulmonary Hypertension, Interstitial Lung Disease (ILD) |
Pulmovant, Inc. | inhaled mosliciguat, Dry Powder Inhaler |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
Phase 3 · Primary Vitreoretinal Lymphoma |
ALDX Aldeyra Therapeutics, Inc. | ICM ADX-2191 injection, Monthly ADX-2191 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-01 in 27d
ESTIMATED |
READOUT
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1
Phase 3 · Nausea and Vomiting, Obesity |
VNDA Vanda Pharmaceuticals Inc. | Tradipitant |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Partici
Phase 2 · RSV Infection, RSV |
ENTA ENANTA PHARMACEUTICALS INC | zelicapavir |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Canc
Phase 3 · Lung Cancer, Lung Metastases |
Vergent Bioscience, Inc. | Abenacianine, Near Infrared (NIR) Imagin |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospit
Phase 2 · Hypertension, Acute Severe Hypertension |
KARD Kardigan, Inc. | Tonlamarsen |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL
Phase 1/2 · Bipolar I Disorder |
ALZN Alzamend Neuro, Inc. | AL001, Lithium carbonate |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Clinical Study Evaluating Licaminlimab for Dry Eye Disease
Phase 2/3 · Dry Eye Disease (DED) |
OCS Oculis Holding AG | Artificial Tear Run-in, licaminlimab, Ve |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
Rademikibart IV for Acute Asthma and COPD Exacerbation
Phase 2 · Asthma Acute, COPD Exacerbation Acute |
Connect Biopharm LLC | Rademikibart |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12 (month) in 27d
ESTIMATED |
READOUT
A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Sus
Phase 3 · Postoperative Ocular Inflammation, Postoperative Ocular Pain |
HROW HARROW, INC. | TRIESENCE (triamcinolone acetonide injec |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-02 in 28d
ESTIMATED |
READOUT
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 t
Phase 3 · Severe Alopecia Areata |
PFE PFIZER INC | Ritlecitinib higher dose, Ritlecitinib l |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-03 in 29d
ESTIMATED |
READOUT
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999,
Phase 2 · Non-Transfusion Dependent Beta-Thalassemia (NTDT) |
REGN REGENERON PHARMACEUTICALS, I | REGN7999 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-03 in 29d
ESTIMATED |
READOUT
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early
Phase 2 · Alzheimer's Disease |
Eisai Inc. | E2814, Lecanemab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-04 in 30d
ESTIMATED |
READOUT
A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth D
Phase 3 · Lyme Disease |
PFE PFIZER INC | VLA15 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-08 in 1mo
ESTIMATED |
READOUT
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Phase 3 · Atrial Fibrillation |
Janssen Research & Development, LL | Milvexian, Apixaban, Apixaban Placebo |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-08 in 1mo
ESTIMATED |
READOUT
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults
Phase 2 · Hidradenitis Suppurativa |
PFE PFIZER INC | Ritlecitinib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-09 in 1mo
ESTIMATED |
READOUT
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis As
Phase 3 · Psychosis Associated With Alzheimer's Disease |
Karuna Therapeutics, Inc., a Brist | KarXT |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-10 in 1mo
ESTIMATED |
READOUT
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People Wi
Phase 3 · Lung Cancer, Non-squamous, Non-small Cell |
Boehringer Ingelheim | zongertinib, pembrolizumab, cisplatin, c |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-10 in 1mo
ESTIMATED |
READOUT
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Ba
Phase 2 · Chronic Kidney Disease and Hypertension |
AZN ASTRAZENECA PLC | Baxdrostat/dapagliflozin, Baxdrostat/Pla |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-11 in 1mo
ESTIMATED |
READOUT
Extended Access of Momelotinib in Adults With Myelofibrosis
Phase 2 · Primary Myelofibrosis |
GlaxoSmithKline | Momelotinib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-11 in 1mo
ESTIMATED |
READOUT
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer Th
Phase 2 · Urothelial Carcinoma |
Seagen, a wholly owned subsidiary | disitamab vedotin, pembrolizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-11 in 1mo
ESTIMATED |
READOUT
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-co
Phase 4 · SARS-CoV-2 |
ModernaTX, Inc. | mRNA-1273, mRNA-1283 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-14 in 1mo
ESTIMATED |
READOUT
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moder
Phase 2 · Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
NVS NOVARTIS AG | AAA617, 68Ga-PSMA-11 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-14 in 1mo
ESTIMATED |
READOUT
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in
Phase 2 · Heart Failure |
BMY BRISTOL MYERS SQUIBB CO | BMS-986435 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-14 in 1mo
ESTIMATED |
READOUT
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
Phase 3 · Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) |
AMGN AMGEN INC | ABP 234, Pembrolizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-14 in 1mo
ESTIMATED |
READOUT
A Study on the Immune Response and Safety of the Second Dose of an Investigation
Phase 3 · Chickenpox |
GlaxoSmithKline | Investigational varicella vaccine, Marke |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-14 in 1mo
ESTIMATED |
READOUT
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20
Phase 2 · Palmoplantar Pustulosis |
LEO Pharma | Delgocitinib cream, Vehicle cream |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-14 in 1mo
ESTIMATED |
READOUT
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help P
Phase 2 · Overweight, Obesity |
NVO NOVO NORDISK A S | NNC0662-0419 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-15 in 1mo
ESTIMATED |
READOUT
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (
Phase 3 · Schizophrenia |
Gedeon Richter Plc. | Cariprazine |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-15 in 1mo
ESTIMATED |
READOUT
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP5
Phase 1/2 · Advanced Solid Tumor, Advanced Malignant Neoplasm |
PMVP PMV Pharmaceuticals, Inc. | rezatapopt, pembrolizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-15 in 1mo
ESTIMATED |
READOUT
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory De
Phase 2/3 · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating |
Janssen Research & Development, LL | Nipocalimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-15 in 1mo
ESTIMATED |
READOUT
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab
Phase 1/2 · Solid Tumor, Adult, Refractory Cancer |
GV20 Therapeutics | GV20-0251, GV20-0251, GV20-0251 and Pemb |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-15 in 1mo
ESTIMATED |
READOUT
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic
Phase 3 · Non-Clear Cell Renal Cell Carcinoma |
EXEL EXELIXIS, INC. | XL092, Nivolumab, Sunitinib Malate |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-15 in 1mo
ESTIMATED |
READOUT
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With ACh
Phase 3 · Generalized Myasthenia Gravis, gMG |
Alexion Pharmaceuticals, Inc. | Gefurulimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-15 in 1mo
ESTIMATED |
READOUT
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Ad
Phase 2 · Locally Advanced Pancreatic Adenocarcinoma |
EXACT Therapeutics AS | Acoustic Cluster Therapy, Modified FOLFI |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-15 in 1mo
ESTIMATED |
READOUT
A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Modera
Phase 3 · Moderate to Severe Glabellar Lines |
Ipsen | Corabotase |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-15 in 1mo
ESTIMATED |
READOUT
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults W
Phase 3 · Moderate to Severe Glabellar Lines |
Ipsen | Corabotase |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-16 in 1mo
ESTIMATED |
READOUT
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodyn
Phase 3 · NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis |
Hoffmann-La Roche | Satralizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-16 in 1mo
ESTIMATED |
READOUT
A Clinical Investigation of a Topical Moisturizer on Skin Barrier Function in Ad
Phase 4 · Sensitive Skin |
Good Molecules, LLC | White petrolatum, Investigational moistu |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-17 in 1mo
ESTIMATED |
READOUT
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Mon
Phase 2 · Alzheimer Disease, Early Onset |
BMY BRISTOL MYERS SQUIBB CO | BMS-986446 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-17 in 1mo
ESTIMATED |
READOUT
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Cr
Phase 2 · Crohn's Disease |
SNY Sanofi | brivekimig |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-17 in 1mo
ESTIMATED |
READOUT
A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participan
Phase 2 · Ulcerative Colitis |
SNY Sanofi | SAR442970 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-17 in 1mo
ESTIMATED |
READOUT
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
Phase 3 · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy |
TAK TAKEDA PHARMACEUTICAL CO LTD | TAK-861 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-18 in 1mo
ESTIMATED |
READOUT
Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymo
Phase 2/3 · Breast Cancer |
Han Xu, M.D., Ph.D., FAPCR, Sponso | Raloxifene - Usual, Raloxifene - Study |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-18 in 1mo
ESTIMATED |
READOUT
Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polym
Phase 2/3 · SCLC |
Han Xu, M.D., Ph.D., FAPCR, Medica | Topotecan - usual, Topotecan - study |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-21 in 2mo
ESTIMATED |
READOUT
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and
Phase 3 · Hidradenitis Suppurativa |
UCB Biopharma SRL | Bimekizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-22 in 2mo
ESTIMATED |
READOUT
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifa
Phase 1/2 · Renal Cell Carcinoma |
Merck Sharp & Dohme LLC | Belzutifan, Palbociclib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-22 in 2mo
ESTIMATED |
READOUT
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
Phase 2 · Alzheimer Disease |
Janssen Pharmaceutica N.V., Belgiu | JNJ-64042056 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-22 in 2mo
ESTIMATED |
READOUT
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of
Phase 2 · Geographic Atrophy |
Boehringer Ingelheim | BI 1584862 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-22 in 2mo
ESTIMATED |
READOUT
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants
Phase 3 · Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD |
Adverum Biotechnologies, Inc. | Ixo-vec, Aflibercept |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-23 in 2mo
ESTIMATED |
READOUT
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Tim
Phase 3 · Asthma |
AZN ASTRAZENECA PLC | Benralizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-23 in 2mo
ESTIMATED |
READOUT
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients
Phase 2 · Prostatic Neoplasm |
NVS NOVARTIS AG | AAA617, AAA517, Piflufolastat F 18, ARPI |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-23 in 2mo
ESTIMATED |
READOUT
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With
Phase 1/2 · Non-Hodgkin Lymphoma |
Cho Pharma Inc. | CHO-H01, CHO-H01 at RP2D, Lenalidomide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-23 in 2mo
ESTIMATED |
READOUT
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-
Phase 2 · Metastatic Castration-resistant Prostate Cancer |
Fusion Pharmaceuticals Inc. | FPI-2265 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-23 in 2mo
ESTIMATED |
READOUT
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzab
Phase 2 · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion |
SNY Sanofi | frexalimab, brivekimig, rilzabrutinib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-25 in 2mo
ESTIMATED |
READOUT
A Study on the Immune Response and Safety of an Investigational Chickenpox Vacci
Phase 3 · Chickenpox |
GlaxoSmithKline | Investigational varicella vaccine_Lot 1, |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-25 in 2mo
ESTIMATED |
READOUT
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spont
Phase 2 · Chronic Spontaneous Urticaria |
PFE PFIZER INC | Ritlecitinib 50 mg, Ritlecitinib 100 mg |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-26 in 2mo
ESTIMATED |
READOUT
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovari
Phase 3 · Carcinoma, Ovarian Epithelial, Ovarian Neoplasms |
CanariaBio Inc. | Oregovomab, Paclitaxel, Carboplatin, Car |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-26 in 2mo
ESTIMATED |
READOUT
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Partici
Phase 3 · Hidradenitis Suppurativa (HS) |
INCY INCYTE CORP | Povorcitinib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-27 in 2mo
ESTIMATED |
READOUT
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Vari
Phase 1/2 · Breast Cancer, Metastatic Breast Cancer |
Stemline Therapeutics, Inc. | Elacestrant, Alpelisib, Everolimus, Ribo |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-27 in 2mo
ESTIMATED |
READOUT
An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution
Phase 2 · Dry Eye Disease (DED) |
Dompé Farmaceutici S.p.A | DFL24498, Vehicle |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-27 in 2mo
ESTIMATED |
READOUT
Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients Wit
Phase 2 · High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion |
Amplexd Therapeutics, Inc. | EGCG and Quinine Sulfate Vaginal Supposi |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-28 in 2mo
ESTIMATED |
READOUT
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed
Phase 2 · Ovarian Neoplasms, Breast Neoplasms |
GlaxoSmithKline | Niraparib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-28 in 2mo
ESTIMATED |
READOUT
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-a
Phase 2 · Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition |
Frantz Viral Therapeutics, LLC | Artesunate |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-29 in 2mo
ESTIMATED |
READOUT
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult P
Phase 2 · Hypercholesterolemia |
REGN REGENERON PHARMACEUTICALS, I | Alirocumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-30 in 2mo
ESTIMATED |
READOUT
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients
Phase 3 · Tuberous Sclerosis Complex |
NVS NOVARTIS AG | everolimus |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-30 in 2mo
ESTIMATED |
READOUT
Combination of TATE and PD-1 Inhibitor in Liver Cancer
Phase 2 · Hepatocellular Carcinoma, Gastric Cancer |
Teclison Ltd. | Nivolumab Injectable Product, Trans-arte |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|
| 2026-12-30 in 2mo
ESTIMATED |
READOUT
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanc
Phase 3 · Renal Cell Carcinoma |
Xynomic Pharmaceuticals, Inc. | Pazopanib, Abexinostat |
ClinicalTrials.gov ↗
✓ Source-checked 2026-11-04
Sponsor-projected date — can change
|